N/A
Manufactured by GlaxoSmithKline LLC
35,585 FDA adverse event reports analyzed
Last updated: 2026-04-14
FLUTICASONE FUROATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by GlaxoSmithKline LLC. The most commonly reported adverse reactions for FLUTICASONE FUROATE include DRUG INEFFECTIVE, DYSPNOEA, ASTHMA, OFF LABEL USE, COUGH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FLUTICASONE FUROATE.
Out of 11,387 classified reports for FLUTICASONE FUROATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 35,585 FDA FAERS reports that mention FLUTICASONE FUROATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, DYSPNOEA, ASTHMA, OFF LABEL USE, COUGH, WHEEZING. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list GlaxoSmithKline LLC in connection with FLUTICASONE FUROATE. Always verify the specific product and NDC with your pharmacist.